Background: The Cromer blood group system consists of seven high-incidence and three low-incidence antigens carried on decay-accelerating factor (DAF). This report describes the identification and characterization of a new Cromer high-incidence antigen, named GUTI.
Study Design And Methods: RT-PCR and sequence analysis were performed on cDNA prepared from a Chilean donor whose serum contained the alloantibody (anti-GUTI). Based on the observed point mutation, a PCR-RFLP assay using MaeII was developed. To map the epitope, DAF-deletion mutants were tested by immunoblotting with anti-GUTI.
Results: Sequence analysis revealed a substitution of 719G>A in DAF in the proband. The proband's parents and two daughters were heterozygotes for 719G>A, one sister whose RBCs typed GUTI- was homozygous for 719A, and one sister had the wild-type DAF (719G). Seven additional heterozygote samples were identified among 214 Chileans. No heterozygotes were found in 197 New York donors. Analysis using DAF-deletion mutants showed the antigenic determinant to be within short consensus repeat (SCR) 4.
Conclusion: This study describes a novel high- incidence antigen (GUTI) in the Cromer blood group system characterized by the amino acid arginine at position 206 in SCR4 of DAF. The GUTI-negative proband has a substitution mutation that predicts for histidine at this position.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1537-2995.2003.00319.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis.
Nat Commun
January 2025
Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Blood transfusion plays a vital role in modern medicine, but frequent shortages occur. Ex vivo manufacturing of red blood cells (RBCs) from universal donor cells offers a potential solution, yet the high cost of recombinant cytokines remains a barrier. Erythropoietin (EPO) signaling is crucial for RBC development, and EPO is among the most expensive media components.
View Article and Find Full Text PDFDual α-globin-truncated erythropoietin receptor knockin restores hemoglobin production in α-thalassemia-derived erythroid cells.
Cell Rep
January 2025
Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA; Eli & Edythe Broad Center for Regeneration Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Bioengineering & Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:
The most severe form of α-thalassemia results from loss of all four copies of α-globin. Postnatally, patients face challenges similar to β-thalassemia, including severe anemia and erythrotoxicity due to the imbalance of β-globin and α-globin chains. Despite progress in genome editing treatments for β-thalassemia, there is no analogous curative option for α-thalassemia.
View Article and Find Full Text PDFThe prevalence of small airways disease and association with handgrip strength in young Hispanic farmworkers.
BMC Pulm Med
December 2024
Department of Medicine, Georgia Prevention Institute, Medical College of Georgia, Augusta University, 1120 15 Street, Augusta, GA, 30912, USA.
Background: Small airways disease (SAD) is a key risk in developing obstructive lung diseases (OLD). Handgrip strength (HGS) is found to be associated with pulmonary function in populations with lung conditions. Hispanics remain the main workforce in farming industry, but their prevalence of lung conditions remain understudied.
View Article and Find Full Text PDFAn immuno-inflammatory profiling of asymptomatic individuals in a malaria endemic area in Uganda.
Acta Trop
December 2024
Department of Laboratory medicine, Lund University, Lund, Sweden; Clinical Chemistry and Pharmacology, Office for Medical Services, Region Skåne, Lund, Sweden. Electronic address:
Malaria caused by Plasmodium falciparum leads to the destruction of red blood cells (RBCs). A better understanding of how naturally immune individuals control infections should be valuable for future vaccine studies. Antibodies against RBCs and RBC surface antigens were measured together with different inflammatory markers in healthy adults living in a malaria endemic area of Uganda and compared to Swedish healthy adults.
View Article and Find Full Text PDFPredicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates.
Nat Commun
September 2024
Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
The ongoing evolution of the SARS-CoV-2 virus has led to a move to update vaccine antigens in 2022 and 2023. These updated antigens were chosen and approved based largely on in vitro neutralisation titres against recent SARS-CoV-2 variants. However, unavoidable delays in vaccine manufacture and distribution meant that the updated booster vaccine was no longer well-matched to the circulating SARS-CoV-2 variant by the time of its deployment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!